NO Re-excision MelanomA - NORMA 2
Condition(s) studied
Investigational drug(s) / intervention(s)
Re-excision: Prior to the re-excision, before any local anesthetic is given, the margin will be measured by a ruler and marked on the skin of the patient. The melanoma free margin of the diagnostic excision may be subtracted from the re-excision margin. The re-excision should be performed by cutting vertically down along the margins of the re-excision for its entire length until the required margin or until the fascia is reached in the depth. Removal of the fascia is left to the resecting surgeon's discretion. Preservation of anatomical structures, such as veins or nerves is allowed, if they are not clearly involved with tumor. In case of melanoma ≥pT3a any margin between 1 and 2 centimeter is accepted according to the surgeons preference. The amount of margin (in mm) taken during the re-excision needs to be documented perioperatively by the surgeon in the operation report. The specimen should be marked for anatomical navigation and sent off for pathological assessment.
No re-excision: In case a patient is randomized toward the no-re-excision treatment arm, there is no need to perform any procedures to the primary tumor site.
Study summary
This multicenter, phase III randomized controlled trial evaluates whether omitting re-excision after complete primary excision of cutaneous melanoma affects patient outcomes. A total of 1,749 patients with pT1b-pT4b cutaneous melanoma without evidence of metastases will be randomized to either standard re-excision according to current guidelines or no re-excision. Sentinel lymph node biopsy and adjuvant systemic therapy will be performed as indicated in both groups.
The primary objective is to compare relapse-free survival (RFS) between the two groups. Secondary objectives include comparisons of overall survival (OS), local recurrence rates, recurrence of in-transit and lymph node metastases, distant metastasis-free survival (DMFS), surgical morbidity, quality of life, and health economic outcomes.
Eligibility
Primary outcome measure(s)
- Relapse-Free Survival (RFS) — From randomization to the first occurrence of melanoma recurrence or melanoma-related death, assessed up to 5 years.
RFS, defined as time from randomization to any first melanoma recurrence or melanoma-related death, whichever occurs first. Any new primary melanoma and/or melanoma in situ will be registered. However, it will not be considered an event for the primary endpoint of RFS.
Trial sites (21)
| Facility | City | Region | Status |
|---|---|---|---|
| Jeroen Bosch Ziekenhuis | 's-Hertogenbosch | Netherlands | Recruiting |
| Noordwest Ziekenhuisgroep | Alkmaar | Netherlands | Recruiting |
| Flevoziekenhuis | Almere Stad | Netherlands | Recruiting |
| Antoni van Leeuwenhoek | Amsterdam | Netherlands | Recruiting |
| Gelre ziekenhuizen | Apeldoorn | Netherlands | Recruiting |
| Rijnstate Ziekenhuis | Arnhem | Netherlands | Recruiting |
| Catharina ziekenhuis | Eindhoven | Netherlands | Not Yet Recruiting |
| Medisch Spectrum Twente | Enschede | Netherlands | Recruiting |
| Groene Hart Ziekenhuis | Gouda | Netherlands | Not Yet Recruiting |
| Martini ziekenhuis | Groningen | Netherlands | Not Yet Recruiting |
| Tergooi MC | Hilversum | Netherlands | Not Yet Recruiting |
| Dijklander Ziekenhuis | Hoorn | Netherlands | Not Yet Recruiting |
| Alrijne Ziekenhuis | Leiden | Netherlands | Not Yet Recruiting |
| Leids Universitair Medisch Centrum | Leiden | Netherlands | Recruiting |
| Maastricht UMC | Maastricht | Netherlands | Not Yet Recruiting |
| Maasstad Ziekenhuis | Rotterdam | Netherlands | Not Yet Recruiting |
| Haaglanden Medisch Centrum | The Hague | Netherlands | Recruiting |
| Haga Ziekenhuis | The Hague | Netherlands | Not Yet Recruiting |
| Diakonessenhuis | Utrecht | Netherlands | Recruiting |
| St. Antonius Ziekenhuis | Utrecht | Netherlands | Not Yet Recruiting |
| Isala Ziekenhuis | Zwolle | Netherlands | Not Yet Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07530887 on ClinicalTrials.gov ↗ ← All trials in the Netherlands